Hit by disappointing clinical data in its lead program, based on an oligonucleotide-based technology, the board of ProNAi Therapeutics Inc. decided in the second half of 2016 to use its healthy balance sheet to license potentially transformative assets in emerging biology with the potential to be next generation therapeutics. Consequently, after assessing more than 200 assets across the globe, the company opted to in-license two DNA damage repair (DDR) programs and relaunch itself as Sierra Oncology.
ProNAI Defects From Oligos to DDR As Sierra Oncology
Sierra Oncology president and CEO Dr Nick Glover tells Mike Ward how the company is rebranding itself from its former incarnation ProNAI Therapeutics, armed with two in-licensed assets focused of DNA damage repair (DDR) and $100m in the bank.